Testing an IOV-4001 infusion for advanced melanoma or lung cancer
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma (Stage IIIC/IIID/IV that can’t be removed) or advanced non-small-cell lung cancer (Stage III/IV that can’t be removed)
- Your prior treatment matches one of the study’s specific rules, including recent progress after certain immunotherapy medicines (anti–PD-1/PD-L1)
- You can do normal daily activities pretty well (ECOG 0 or 1)
- Doctors can find at least one spot of cancer that can be measured after a needed procedure for treatment planning
- Your heart (and sometimes lung) tests meet the trial’s safety limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment, IOV-3001 and lifileucel, for people with advanced melanoma that has not responded to standard immunotherapy and cannot be surgically removed. It aims to see if this cellular therapy is safe and effective.
This trial tests an investigational cell therapy called IOV-5001 for people with advanced solid tumors (lung, breast, colon, or head and neck cancer) that has worsened after standard treatments. The goal is to see if this therapy can help shrink tumors or slow their growth.
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
This study is testing a new blood test called IOpener®-Melanoma to see if it can predict which patients with advanced melanoma will respond well to immunotherapy. The goal is to better match treatments to people who will benefit most.
This trial tests a new drug called OPM-101 combined with an immunotherapy (anti-PD-1) for people with advanced melanoma that has stopped responding to anti-PD-1 treatment. The goal is to see if the combination can overcome resistance and shrink tumors.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
Hear when a new Unresectable Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.